Top 5 Companies Operating in the Competitive Terrain of the Global Typhoid Fever Vaccine Market

Typhoid is one of the most commonly occurring forms of bacterial infection. If the disease is not prevented or treated on time, it may prove fatal for the patients.

A wide array of companies have formulated effective vaccines to prevent the occurrence of typhoid or reduce its severity to a massive extent.

The top 5 players leading the Typhoid Fever Vaccine Market are-

GlaxoSmithKline PLC

Market Position or History

• In August 2022, GlaxoSmithKline announced the acquisition of Affinivax, Inc. This deal will help the company to solidify its portfolio of vaccines and medicines.
• In December 2018, GlaxoSmithKline inked a partnership deal with Pfizer Inc. to jointly enhance their consumer health business.

Business Overview and Strategy

GlaxoSmithKline PLC also known as GSK PLC was established on December 27, 2000. The pharmaceutical and biotechnology company emerged as a result of the merger between SmithKline Beecham and Glaxo WellCome. It is currently headquartered in Brentford, United Kingdom. It is known for developing the first ever vaccine for malaria, named RTS, S. In fact, it was the first ever vaccine developed for a parasitic disease. With extensive R&D activities the company also developed an effective vaccine for typhoid named Typherix.

GSK’s primary focus is on disease prevention and treatment. It has turn into a full pledged biopharma company that emphasizes on creating speciality medicines and vaccines. It amalgamates talent, science, and technology to create wonders in the biopharma sector. It believes in operating with complete transparency.

Sanofi S.A.

Market Position or History

• In September 2021, Sanofi announced the acquisition of Kadmon Holdings, Inc. with an aim to improve its General Medicines portfolio.
• In March 2020, Sanofi inked a collaboration deal with IGM Biosciences, Inc. Under the terms of this agreement, both the companies will work on the creation, development, manufacturing, and commercialization of the IgM antibody agonists.

Business Overview and Strategy

Sanofi S.A is a France based pharmaceutical and healthcare company. It was originally founded in 1973 and was later merged with Synthelabo in 1999. It operated under the name of Sanofi-Synthelabo till 2004. But later that  year it had  a merger deal with Aventis post which its name was changed to Sanofi-Aventis. In 2011, it starting operating under the name of Sanofi S.A. The company produces pharmaceutical products pertaining to seven major areas namely, internal medicines, diabetes, cardiovascular, central nervous  system, thrombosis, oncology, along with vaccines.

Typhim Vi, an efficient vaccine for typhoid which was developed in 1986 was licenced to Sanofi in 1994. This vaccine is highly effective  in treating and preventing typhoid in children as well as adults.

Sanofi S.A. focusses on addressing the needs of the patients by  developing and commercializing efficient medicines and vaccines for target diseases. It believes is making complete use of the miracles of science to enhance the lives of the masses. It generates commendable revenues every years by producing and selling pharmaceutical entities.

PaxVax Corporation

Market Position or History

• In August 2018, PaxVax Corporation was acquired by Emergent BioSolutions for a whopping amount of USD 270 million.

Business Overview and Strategy

PaxVaX Corporation was established in 2006 as a vaccine start-up company. It is known for creating oral vaccines for the prevention of infectious diseases. It is well known for developing an adenovirus based oral vaccine technology.

The company has developed the first ever oral vaccine for typhoid named Vivotif.  PaxVax has always been sticking to its primary motto, i.e. to develop vaccines for the prevention of lethal  infectious ailments. It makes used of advanced technologies and scientific innovations to diversify its product portfolio. It earns most of its financial revenue by formulating effective business strategies in the biodefense and travellers vaccines vertical.

Bharat Biotech International Limited

Market Position or History

• In February 2019, Bharat Biotech announced the acquisition of Chiron Behring Vaccines with an aim to enhance its vaccine portfolio.

Business Overview and Strategy

Established in 1996, Bharat Biotech is headquartered in Hyderabad, India. It develops and manufactures a wide array of pharmaceuticals and healthcare products. The  company predominantly specializes in drug development, vaccine manufacturing, and drug discovery. Suchitra Ella and  Krishna Ella are the founders of this enterprise.

Bharat Biotech is known for developing the first ever clinically proven conjugate  typhoid vaccine. The vaccine can be administered to infants and children who are over six months of age. The company aims to delivery high quality medicines  and vaccines at an affordable cost to the masses. It’s motto is to prevail over lethal diseases by using the wonders of  science and technology.

Shanghai Institute of Biological Products Co. Ltd.

Market Position or History

• In July 2013, Shanghai Institute of Biological Products Co. Ltd. inked a collaboration deal with Pharming Group. Under the terms of this deal the latter will transfer its high end technology platforms to Shanghai Institute.

Business Overview and Strategy

The  company was established  in 1949 and is presently headquartered in Shanghai, China. It mainly specializes in the production and manufacturing of virus and bacterial vaccines, analogous products, and toxoids. It has developed numerous core vaccines  for the prevention of a wide range  of infectious ailments like typhoid.

It mainly focuses on biological research to discover highly effective drugs and vaccines. The company believes in making complete use of its resources to meet its growth goals. It is worth noting that the firm has managed to garner an annual revenue range of USD 1 million to USD 5 million.